Method of eliciting a CD8+ cytotoxic response in hepatocellular carcinoma patients with a population of activated T cells
A method of eliciting an immune response in a patient who has a cancer includes administering to said patient a composition containing a population of activated T cells that selectively recognize the cancer cells in the patient that aberrantly express a peptide consisting of the amino acid sequence of IYVTSIEQI (SEQ ID NO: 214), in which the peptide is in a complex with an MHC molecule.
1. A method of eliciting a CD8+cytotoxic T cell response in an HLA-A*24+patient who has cancer that presents at the cell surface a peptide consisting of the amino acid sequence of IYVTSIEQI (SEQ ID NO: 214), comprising
administering to said identified patient a composition comprising a population of activated antigen-specific CD8+cytotoxic T cells to kill the cancer cells in the identified patient,
wherein the population of activated antigen-specific CD8+cytotoxic T cells recognize the cancer cells by interacting through their T cell receptor (TCR) with a peptide consisting of the amino acid sequence of IYVTSIEQI (SEQ ID NO: 214) in a complex with HLA-A*24 presented at the surface of the cancer cells,
wherein the activated antigen-specific CD8+cytotoxic T cells are autologous to the patient,
wherein the cancer is hepatocellular carcinoma, brain cancer, non-small cell lung cancer, or kidney cancer.
2. The method of claim 1 , wherein the composition further comprises an adjuvant.
3. The method of claim 2 , wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, polyinosinic:polycytidylic acid (poly-(I:C)) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
4. The method of claim 3 , wherein the adjuvant is IL-7.
5. The method of claim 3 , wherein the adjuvant is IL-15.
6. The method of claim 3 , wherein the adjuvant is IL-21.
7. The method of claim 1 , wherein the cancer is hepatocellular carcinoma.
8. The method of claim 1 , wherein the cancer is brain cancer.
9. The method of claim 1 , wherein the cancer is non-small cell lung cancer.
10. The method of claim 1 , wherein the cancer is kidney cancer.
11. A method of eliciting a CD8+cytotoxic T cell response in an HLA-A*24+patient who has cancer that presents at the cell surface a peptide consisting of the amino acid sequence of IYVTSIEQI (SEQ ID NO: 214), wherein the cancer cells overexpress a GABAA receptor theta subunit (GABRQ) polypeptide comprising the amino acid sequence of IYVTSIEQI (SEQ ID NO: 214) as compared to a panel of normal tissues, wherein the cancer cells present at the cell surface a peptide consisting of the amino acid sequence of IYVTSIEQI (SEQ ID NO: 214) in a complex with HLA-A*24, comprising
administering to said patient who has cancer a composition comprising a population of activated antigen-specific CD8+cytotoxic T cells to kill the cancer cells in the patient,
wherein the population of the activated antigen-specific CD8+cytotoxic T cells recognize the cancer cells by interacting through their T cell receptor (TCR) with a peptide consisting of the amino acid sequence of IYVTSIEQI (SEQ ID NO: 214) in a complex with HLA-A*24 presented at the surface of the cancer cells,
wherein the activated antigen-specific CD8+cytotoxic T cells are autologous to the patient,
wherein the cancer is hepatocellular carcinoma, brain cancer, non-small cell lung cancer, or kidney cancer.
12. The method of claim 11 , wherein the composition further comprises an adjuvant.
13. The method of claim 12 , wherein the adjuvant is selected from the group consisting of anti-CD40 antibody, imiquimod, resiquimod, Granulocyte Macrophage Colony Stimulating Factor (GM-CSF), cyclophosphamide, Sunitinib, bevacizumab, interferon-alpha, interferon-beta, CpG oligonucleotides and derivatives, polyinosinic:polycytidylic acid (poly-(I:C)) and derivatives, RNA, sildenafil, particulate formulations with poly(lactide co-glycolide) (PLG), virosomes, interleukin (IL)-1, IL-2, IL-4, IL-7, IL-12, IL-13, IL-15, IL-21, and IL-23.
14. The method of claim 13 , wherein the adjuvant is IL-7.
15. The method of claim 13 , wherein the adjuvant is IL-15.
16. The method of claim 13 , wherein the adjuvant is IL-21.
17. The method of claim 11 , wherein the cancer is hepatocellular carcinoma.
18. The method of claim 11 , wherein the cancer is brain cancer.
19. The method of claim 11 , wherein the cancer is non-small cell lung cancer.
20. The method of claim 11 , wherein the cancer is kidney cancer.